Neuropsychiatric symptoms in Alzheimer's disease: Past, present, and future
Alzheimer's & Dementia · 2026-01 · 22 (1)
DOI: 10.1002/alz.71077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 08.01.2026. Verfasst von Constantine G Lyketsos und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Depression. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Johns Hopkins Alzheimer's Disease Research Center.
Themen: Demenz
Abstract (Originalsprache)
Noncognitive neuropsychiatric symptoms (NPS; e.g., depression, agitation) are nearly universal throughout the course of Alzheimer's disease (AD), cause significant adverse impact to patients and caregivers, and are associated with more rapid progression to severe dementia. Although the importance and presence of NPS was recognized by Dr. Alois Alzheimer himself, it was a series of research roundtables in the 2010s that propelled the understanding and treatment of NPS in AD forward. The mild behavioral impairment (MBI) construct was developed as a complementary behavioral analogue to mild cognitive impairment, solidifying the importance of NPS prior to dementia onset. Neurobiological underpinnings of NPS are being studied and the NPS treatment pipeline includes novel therapeutics, repurposing of existing pharmaceuticals, and non‐pharmacologic interventions. The Alzheimer's Disease Research Centers and The National Alzheimer's Coordinating Center, being recognized in this special issue, have played a pivotal role in the recognition and study of NPS in AD. Highlights Noncognitive neuropsychiatric symptoms (NPS) are nearly universal throughout the course of Alzheimer's disease (AD), cause significant adverse impact to patients and caregivers, and are associated with more rapid progression to severe dementia. A series of research roundtables in the last decade and a half have propelled the understanding and treatment of NPS in AD forward. The mild behavioral impairment (MBI) construct was developed as a complementary behavioral analogue to mild cognitive impairment, solidifying the importance of NPS prior to dementia onset. Neurobiological underpinnings of NPS are being studied and the treatment pipeline includes novel therapeutics, repurposing of pharmaceuticals, and non‐pharmacologic interventions. The Alzheimer's Disease Research Centers and The National Alzheimer's Coordinating Center have played a pivotal role in the recognition and study of NPS in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Förderung
- NIA NIH HHS
- Johns Hopkins Alzheimer's Disease Research Center
Zitieren
APA
Lyketsos, C. G., & Peters, M. E. (2026). Neuropsychiatric symptoms in Alzheimer's disease: Past, present, and future. Alzheimer's & Dementia, 22(1). https://doi.org/10.1002/alz.71077
Vancouver
Lyketsos CG, Peters ME. Neuropsychiatric symptoms in Alzheimer's disease: Past, present, and future. Alzheimer's & Dementia. 2026;22(1). doi:10.1002/alz.71077
BibTeX
@article{Lyketsos2026,
author = {Lyketsos, Constantine G and Peters, Matthew E},
title = {Neuropsychiatric symptoms in Alzheimer's disease: Past, present, and future},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {1},
doi = {10.1002/alz.71077}
}
EUVIMED